Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2017

01-07-2017 | Review

Natural History of Pancreatic Cysts

Authors: Alexander Larson, Richard S. Kwon

Published in: Digestive Diseases and Sciences | Issue 7/2017

Login to get access

Abstract

Pancreatic cystic neoplasms are discovered with increasing frequency. Accurate knowledge of the natural history of cystic neoplasms is crucial to develop useful and cost-effective strategies for surveillance and surgical resection. To date, the natural history of cystic neoplasms is still incomplete due to lack of adequate diagnostic accuracy in the absence of surgical pathology. Nevertheless, current evidence points to risk factors for malignant transformation to help clinical management. New biomarkers that accurately distinguish cyst neoplasms and those most likely to progress to cancer would help clarify the natural history of cystic neoplasms.
Literature
1.
Zanini N, Giordano M, Smerieri E, et al. Estimation of the prevalence of asymptomatic pancreatic cysts in the population of San Marino. Pancreatology. 2015;15:417–422.CrossRefPubMed
2.
3.
Chang YR, Park JK, Jang JY, et al. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: large-scale, single-center cohort study. Medicine (Baltimore). 2016;95:e5535.CrossRef
4.
Tolstunov L. An illusive cyst: should my mother have had her surgery? JOP. 2013;14:522–524.PubMed
5.
Othman MO, Buscaglia JM. Get ready to meet the growing demand from patients with pancreatic cysts. Clin Gastroenterol Hepatol. 2016;14:594–596.CrossRefPubMed
6.
Klibansky DA, Reid-Lombardo KM, Gordon SR, et al. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2012;10:555–558.CrossRefPubMed
7.
Wu BU, Sampath K, Berberian CE, et al. Prediction of malignancy in cystic neoplasms of the pancreas: a population-based cohort study. Am J Gastroenterol. 2014;109:121–129. (quiz 130).CrossRefPubMed
8.
Munigala S, Gelrud A, Agarwal B. Risk of pancreatic cancer in patients with pancreatic cyst. Gastrointest Endosc. 2016;84:81–86.CrossRefPubMed
9.
Fernandez-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138:427–433. (discussion 433–434).CrossRefPubMedPubMedCentral
10.
Reames BN, Scally CP, Frankel TL, et al. National trends in resection of cystic lesions of the pancreas. HPB (Oxford). 2016;18:375–382.CrossRef
11.
Adsay NV. Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg. 2008;12:401–404.CrossRefPubMed
12.
Brugge WR, Lauwers GY, Sahani D, et al. Cystic neoplasms of the pancreas. N Engl J Med. 2004;351:1218–1226.CrossRefPubMed
13.
Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012;152:S4–S12.CrossRefPubMedPubMedCentral
14.
Strobel O, Z’Graggen K, Schmitz-Winnenthal FH, et al. Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion. 2003;68:24–33.CrossRefPubMed
15.
Wasel BA, Keough V, Huang WY, et al. Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. BMJ Case Rep. 2013;2013.
16.
Johnson CD, Stephens DH, Charboneau JW, et al. Cystic pancreatic tumors: CT and sonographic assessment. AJR Am J Roentgenol. 1988;151:1133–1138.CrossRefPubMed
17.
Curry CA, Eng J, Horton KM, et al. CT of primary cystic pancreatic neoplasms: can CT be used for patient triage and treatment? AJR Am J Roentgenol. 2000;175:99–103.CrossRefPubMed
18.
Kimura W, Moriya T, Hirai I, et al. Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas. 2012;41:380–387.CrossRefPubMed
19.
Huang P, Staerkel G, Sneige N, et al. Fine-needle aspiration of pancreatic serous cystadenoma: cytologic features and diagnostic pitfalls. Cancer. 2006;108:239–249.CrossRefPubMed
20.
van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc. 2005;62:383–389.CrossRefPubMed
21.
Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65:305–312.CrossRefPubMed
22.
Tseng JF, Warshaw AL, Sahani DV, et al. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg. 2005;242:413–419. (discussion 419–421).PubMedPubMedCentral
23.
El-Hayek KM, Brown N, O’Rourke C, et al. Rate of growth of pancreatic serous cystadenoma as an indication for resection. Surgery. 2013;154:794–800. (discussion 800–802).CrossRefPubMed
24.
Malleo G, Bassi C, Rossini R, et al. Growth pattern of serous cystic neoplasms of the pancreas: observational study with long-term magnetic resonance surveillance and recommendations for treatment. Gut. 2012;61:746–751.CrossRefPubMed
25.
Crippa S, Fernandez-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010;8:213–219.CrossRefPubMed
26.
Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol. 1999;23:410–422.CrossRefPubMed
27.
Izumo A, Yamaguchi K, Eguchi T, et al. Mucinous cystic tumor of the pancreas: immunohistochemical assessment of “ovarian-type stroma”. Oncol Rep. 2003;10:515–525.PubMed
28.
Kosmahl M, Pauser U, Peters K, et al. Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch. 2004;445:168–178.CrossRefPubMed
29.
30.
Lai EC, Lau WY. Diagnosis and management strategy for cystic neoplasm of the pancreas. Int J Surg. 2009;7:7–11.CrossRefPubMed
31.
Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–1336.CrossRefPubMed
32.
Cizginer S, Turner BG, Bilge AR, et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40:1024–1028.CrossRefPubMed
33.
Nilsson LN, Keane MG, Shamali A, et al. Nature and management of pancreatic mucinous cystic neoplasm (MCN): a systematic review of the literature. Pancreatology. 2016;16:1028–1036.CrossRefPubMed
34.
Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRefPubMed
35.
Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, et al. Primary pancreatic cystic neoplasms revisited: part II. Mucinous cystic neoplasms. Surg Oncol. 2011;20:e93–e101.CrossRefPubMed
36.
Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg. 2008;247:571–579.CrossRefPubMedPubMedCentral
37.
Reddy RP, Smyrk TC, Zapiach M, et al. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer. Clin Gastroenterol Hepatol. 2004;2:1026–1031.CrossRefPubMed
38.
Sonnenday CJ, Simeone DM. “Criminal” profiling of the pancreas: when is aggressive therapy indicated for a non-aggressive entity? Ann Surg. 2008;247:580–582.CrossRefPubMed
39.
Roch AM, Bigelow K, Schmidt CM II, et al. Management of undifferentiated solitary mucinous cystic lesion of the pancreas: a clinical dilemma. J Am Coll Surg. 2017.
40.
Zamboni G, Hirabayashi K, Castelli P, et al. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol. 2013;27:299–322.CrossRefPubMed
41.
Yamao K, Yanagisawa A, Takahashi K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. Pancreas. 2011;40:67–71.CrossRefPubMed
42.
Lewis GH, Wang H, Bellizzi AM, et al. Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2013;37:601–605.CrossRefPubMedPubMedCentral
43.
Sarr MG, Carpenter HA, Prabhakar LP, et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg. 2000;231:205–212.CrossRefPubMedPubMedCentral
44.
Wilentz RE, Albores-Saavedra J, Zahurak M, et al. Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 1999;23:1320–1327.CrossRefPubMed
45.
Le Borgne J, de Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg. 1999;230:152–161.CrossRefPubMedPubMedCentral
46.
Park JW, Jang JY, Kang MJ, et al. Mucinous cystic neoplasm of the pancreas: is surgical resection recommended for all surgically fit patients? Pancreatology. 2014;14:131–136.CrossRefPubMed
47.
Del Chiaro M, Verbeke C, Salvia R, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45:703–711.CrossRefPubMed
48.
Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013;258:466–475.CrossRefPubMed
49.
Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–685. (discussion 685–687).CrossRefPubMedPubMedCentral
50.
Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology. 2007;133:72–79.CrossRefPubMedPubMedCentral
51.
Matthaei H, Norris AL, Tsiatis AC, et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255:326–333.CrossRefPubMedPubMedCentral
52.
Barron MR, Roch AM, Waters JA, et al. Does preoperative cross-sectional imaging accurately predict main duct involvement in intraductal papillary mucinous neoplasm? J Gastrointest Surg. 2014;18:447–455. (discussion 5455–5456).CrossRefPubMed
53.
Fritz S, Klauss M, Bergmann F, et al. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk. Ann Surg. 2014;260:848–855. (discussion 855–856).CrossRefPubMed
54.
Fong ZV, Ferrone CR, Lillemoe KD, et al. Intraductal papillary mucinous neoplasm of the pancreas: current state of the art and ongoing controversies. Ann Surg. 2016;263:908–917.CrossRefPubMed
55.
Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015;261:976–983.CrossRefPubMed
56.
Ceppa EP, Roch AM, Cioffi JL, et al. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm. Surgery. 2015;158:937–944. (discussion 944–945).CrossRefPubMed
57.
Sahora K, Fernandez-del Castillo C, Dong F, et al. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery. 2014;156:611–621.CrossRefPubMed
58.
Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.CrossRefPubMed
59.
Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, et al. Primary pancreatic cystic neoplasms revisited. Part III. Intraductal papillary mucinous neoplasms. Surg Oncol. 2011;20:e109–e118.CrossRefPubMed
60.
Anand N, Sampath K, Wu BU. Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:913–921.CrossRefPubMed
61.
Sultana A, Jackson R, Tim G, et al. What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and meta-analyses. Clin Transl Gastroenterol. 2015;6:e130.CrossRefPubMedPubMedCentral
62.
Ohtsuka T, Kono H, Nagayoshi Y, et al. An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2012;151:76–83.CrossRefPubMed
63.
Roch AM, Ceppa EP, DeWitt JM, et al. International Consensus Guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative. HPB (Oxford). 2014;16:929–935.CrossRef
64.
Kang MJ, Lee KB, Jang JY, et al. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN. Pancreas. 2013;42:1267–1274.CrossRefPubMed
65.
Ohtsuka T, Kono H, Tanabe R, et al. Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg. 2012;204:44–48.CrossRefPubMed
66.
Tanno S, Nakano Y, Sugiyama Y, et al. Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology. 2010;10:173–178.CrossRefPubMed
67.
Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40:571–580.CrossRefPubMed
68.
69.
Furukawa T, Kloppel G, Adsay NV, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794–799.CrossRefPubMed
70.
Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60:509–516.CrossRefPubMed
71.
Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;60:1712–1720.CrossRefPubMedPubMedCentral
72.
Koh YX, Zheng HL, Chok AY, et al. Systematic review and meta-analysis of the spectrum and outcomes of different histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms. Surgery. 2015;157:496–509.CrossRefPubMed
73.
Marchegiani G, Mino-Kenudson M, Ferrone CR, et al. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015;220:839–844.CrossRefPubMed
74.
Schaberg KB, DiMaio MA, Longacre TA. Intraductal papillary mucinous neoplasms often contain epithelium from multiple subtypes and/or are unclassifiable. Am J Surg Pathol. 2016;40:44–50.CrossRefPubMed
75.
Yoon WJ, Daglilar ES, Mino-Kenudson M, et al. Characterization of epithelial subtypes of intraductal papillary mucinous neoplasm of the pancreas with endoscopic ultrasound and cyst fluid analysis. Endoscopy. 2014;46:1071–1077.CrossRefPubMed
76.
Hara T, Ikebe D, Odaka A, et al. Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg. 2013;257:1103–1111.CrossRefPubMed
77.
Vege SS, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–822.CrossRefPubMed
78.
Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788–797. (discussion 797–799).CrossRefPubMedPubMedCentral
79.
Kang MJ, Jang JY, Lee KB, et al. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014;260:356–363.CrossRefPubMed
80.
Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143:639–646. (discussion 646).CrossRefPubMed
81.
Takahashi H, Nakamori S, Nakahira S, et al. Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas. Ann Surg Oncol. 2006;13:955–960.CrossRefPubMed
82.
Marchegiani G, Mino-Kenudson M, Ferrone CR, et al. Patterns of recurrence after resection of IPMN: who, when, and how? Ann Surg. 2015;262:1108–1114.CrossRefPubMed
83.
Xourafas D, Tavakkoli A, Clancy TE, et al. Noninvasive intraductal papillary mucinous neoplasms and mucinous cystic neoplasms: recurrence rates and postoperative imaging follow-up. Surgery. 2015;157:473–483.CrossRefPubMed
84.
He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–665. (discussion 665–667).CrossRefPubMedPubMedCentral
85.
Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123:1500–1507.CrossRefPubMed
86.
Jang JY, Kim SW, Lee SE, et al. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol. 2008;15:199–205.CrossRefPubMed
87.
Adsay NV, Conlon KC, Zee SY, et al. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer. 2002;94:62–77.CrossRefPubMed
88.
Crippa S, Bassi C, Salvia R, et al. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut. 2017;66:495–506.CrossRefPubMed
89.
Daude M, Muscari F, Buscail C, et al. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol. 2015;21:2658–2667.CrossRefPubMedPubMedCentral
90.
Ogura T, Masuda D, Kurisu Y, et al. Potential predictors of disease progression for main-duct intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol Hepatol. 2013;28:1782–1786.CrossRefPubMed
91.
Uehara H, Ishikawa O, Ikezawa K, et al. A natural course of main duct intraductal papillary mucinous neoplasm of the pancreas with lower likelihood of malignancy. Pancreas. 2010;39:653–657.CrossRefPubMed
92.
Takuma K, Kamisawa T, Anjiki H, et al. Predictors of malignancy and natural history of main-duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2011;40:371–375.CrossRefPubMed
93.
Pausawasdi N, Heidt D, Kwon R, et al. Long-term follow-up of patients with incidentally discovered pancreatic cystic neoplasms evaluated by endoscopic ultrasound. Surgery. 2010;147:13–20.CrossRefPubMed
94.
Pelaez-Luna M, Chari ST, Smyrk TC, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol. 2007;102:1759–1764.CrossRefPubMed
95.
Crippa S, Capurso G, Camma C, et al. Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: a systematic review and meta-analysis. Dig Liver Dis. 2016;48:473–479.CrossRefPubMed
96.
Ball CG, Howard TJ. Natural history of intraductal papillary mucinous neoplasia: how much do we really know? World J Gastrointest Surg. 2010;2:368–372.CrossRefPubMedPubMedCentral
97.
Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:824 e22–848 e22.CrossRef
98.
Kwong WT, Hunt GC, Fehmi SM, et al. Low rates of malignancy and mortality in asymptomatic patients with suspected neoplastic pancreatic cysts beyond 5 years of surveillance. Clin Gastroenterol Hepatol. 2016;14:865–871.CrossRefPubMed
Metadata
Title
Natural History of Pancreatic Cysts
Authors
Alexander Larson
Richard S. Kwon
Publication date
01-07-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4542-x

Other articles of this Issue 7/2017

Digestive Diseases and Sciences 7/2017 Go to the issue

Review

Medical Management of Pain in Chronic Pancreatitis

Review

Epidemiology of Recurrent Acute and Chronic Pancreatitis: Similarities and Differences

Editorial

Editors’ Introduction to the Chronic Pancreatitis and Pancreatic Cysts Special Issue

Review

Autoimmune Pancreatitis

Review

Novel Biomarkers for Pancreatic Cysts

Review

Surgical Approaches to Chronic Pancreatitis: Indications and Techniques

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits